PolTREG S.A.
Dan Shelly serves as the Chief Business Development Officer at PolTREG S.A. since February 2024 and is involved with BioStem Technologies as a member of the Scientific Advisory Board and on the Board of Directors at BioSolution Designs. Prior experience includes Vice President of Business Development and Alliances at Prescient Therapeutics, where Dan held the position until February 2024, and Director of Global Business Development at PATH, focusing on innovative technologies for global health. Dan was previously the Director of Business Development at Albumedix and Novozymes Biopharma, with an earlier role at Meridian Life Science, Inc. Education includes an MBA from the University of Cincinnati, a PhD in Molecular Physiology from Florida State University, an MA in Physiology from William & Mary, a BS in Biology from Lehigh University, and postdoctoral training in Molecular Physiology at the University of Cincinnati College of Medicine.
This person is not in any teams
This person is not in any offices
PolTREG S.A.
PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS). PolTREG has very promising results regarding the safety and efficacy of TREGS therapy (completed phase I/II clinical trials in T1D and phase I in MS), ready for the next phase of trials. The company is after EMA Scientific Advice procedure.